Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study.

Multi-cohort GWAS (Knight-ADRC, DIAN, ADSP) to identify modifier variants of autosomal dominant Alzheimer's disease expressivity

This multi-cohort GWAS on carriers of PSEN1, PSEN2, or APP mutations (autosomal dominant Alzheimer's disease) identifies modifier variants influencing clinical variability — notably age at onset and severity. Knight-ADRC, DIAN, and ADSP cohorts are combined to maximize power. Discovered modifiers shed light on pathogenic mechanisms and offer targets for therapeutic interventions in this genetically defined patient subgroup.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Autosomal dominant AD is a unique model for studying genetic modifiers: the causal variant is known, allowing isolation of modifier effects on expressivity. These Lancet Neurology data have direct impact on genetic counseling of PSEN1/PSEN2/APP families — notably for contextualizing age-at-onset variability, often a major source of anxiety.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 2/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 8/10